Read More Pharma Industry News What clinicians and regulators will watch next after neflamapimod’s MRI results CervoMed Inc. (NASDAQ: CRVO) reveals neflamapimod MRI data. Discover what clinicians and regulators will watch next in DLB trials. bySoujanya RaviApril 24, 2026